Lineage Cell Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Lineage Cell Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Lineage Cell Therapeutics Inc Strategy Report
- Understand Lineage Cell Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lineage Cell Therapeutics Inc (Lineage) formerly known as BioTime Inc, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. Lineage’s lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration, Opc1 in acute spinal cord injury, and Vac2 for non-small cell lung cancer. The company has subsidiaries in Israel, Singapore, and the US. Lineage is headquartered in Carlsbad, California, the US.
Lineage Cell Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Cell/Drug Delivery |
Renevia: |
Facial Lipoatrophy |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In February, the company entered into an option and license agreement with Eterna Therapeutics Inc for the development of novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell lines. |
2022 | New Products/Services | In November, the company's partner Genentech launched a Phase 2a, multicenter, open-label, single arm clinical study of RG6501 (OpRegen). |
2021 | Contracts/Agreements | In June, the company entered into an option agreement with Amasa Therapeutics for supply and use of Clinical-Grade Hystem |
Competitor Comparison
Key Parameters | Lineage Cell Therapeutics Inc | Baxter International Inc | Astellas Pharma Inc | Kineta Inc | Athersys Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Japan | United States of America | United States of America |
City | Carlsbad | Deerfield | Chuo-Ku | Mercer Island | Cleveland |
State/Province | California | Illinois | Tokyo | Washington | Ohio |
No. of Employees | 75 | 60,000 | 14,484 | 11 | 24 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Brian M. Culley | Chief Executive Officer | Executive Board | 2018 | 51 |
Jill Howe | Chief Financial Officer | Senior Management | 2022 | - |
Alfred D. Kingsley | Chairman | Non Executive Board | 2009 | 77 |
George A. Samuel | General Counsel; Secretary | Senior Management | 2021 | - |
Rami Skaliter | Chief Executive Officer - Cell Cure Neurosciences | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward